Osteopore Secures $20M Convertible Note to Drive Expansion and Financial Stability

About Osteopore Limited

Osteopore Limited (Osteopore, ASX: OSX) is a medical technology company specialising in regenerative implants that promote natural bone healing using 3D-printed biomaterials. With a growing global presence, the company focuses on innovative solutions for craniofacial and orthopaedic applications. As of 11 February 2025, its share price was AUD 0.0387. The latest capital raise aims to support expansion, technology development, and financial restructuring, reinforcing its long-term growth strategy.

Convertible Note Details Provide Flexible Funding with Investor Upside

Osteopore has entered a strategic partnership with Advance Opportunities Fund, a Cayman Islands-based investment group, to issue $20 million in Convertible Notes. The capital will be raised in four tranches of $5 million, with the first tranche expected by 14 February 2025.

The Convertible Notes mature in 36 months and carry a 4.0% annual interest rate, paid quarterly. Investors have the flexibility to convert their notes into OSX shares at 80% of the five-day VWAP prior to conversion, allowing potential value appreciation. This structure provides liquidity and growth capital without immediate equity dilution, supporting the company’s expansion efforts while maintaining financial flexibility.

Capital Allocation to Strengthen Operations, Reduce Debt, and Drive Innovation

The funds raised will be deployed across three core areas: expanding operations, advancing product development, and reducing existing financial obligations. A portion of the funds will be allocated to loan repayments, improving the company’s balance sheet strength and financial stability.

In addition, Osteopore is expected to channel resources into R&D and commercialisation of its biodegradable implant technology, furthering its presence in key international markets. The investment aligns with the company’s long-term vision of scaling its market reach while reinforcing its technological leadership in regenerative medicine.

Strengthening Market Position in the Growing Regenerative Medicine Sector

Osteopore’s innovative biodegradable implants position it as a key player in the rapidly expanding regenerative medicine market, where demand for biomedical solutions that support natural healing is rising. The successful execution of this capital raise is expected to accelerate product innovation, commercial expansion, and financial resilience, reinforcing investor confidence.

With a clear roadmap for capital deployment, Osteopore remains focused on enhancing shareholder value through strategic growth initiatives. Key upcoming developments, including fund allocation updates, potential acquisitions, and operational milestones, will be critical indicators for investors monitoring the company’s progress.